gyki 52466 and ibogaine

gyki 52466 has been researched along with ibogaine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Molliver, ME; O'Hearn, E	1

Other Studies

1 other study(ies) available for gyki 52466 and ibogaine

Article	Year
Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine. Neuroscience, 2004, Volume: 127, Issue:2 Topics: Animals; Benzodiazepines; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Ibogaine; Male; Nerve Degeneration; Neurotoxins; Olivary Nucleus; Purkinje Cells; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Synapses; Synaptic Transmission; Up-Regulation	2004

Article

Year

Administration of a non-NMDA antagonist, GYKI 52466, increases excitotoxic Purkinje cell degeneration caused by ibogaine.

Neuroscience, 2004, Volume: 127, Issue:2

Topics: Animals; Benzodiazepines; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Ibogaine; Male; Nerve Degeneration; Neurotoxins; Olivary Nucleus; Purkinje Cells; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Synapses; Synaptic Transmission; Up-Regulation

2004